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Non-affective psychosisThe objective of the study is to examine the association of baseline total antioxidant status (TAS) and glutathione
(GSH) levelswith short- and long-term cognitive functioning in patientswith early onsetﬁrst-episode psychosis,
comparing affective and non-affective psychoses.
We analysed 105 patients with an early onset-ﬁrst episode psychosis (age 9–17 years) and 97 healthy controls.
Blood samples were taken at admission for measurement of TAS and GSH, and cognitive performance was
assessed at baseline and at 2 years of follow-up. Regression analysis was used to assess the relationship between
TAS/GSH levels at baseline and cognitive performance at both time points, controlling for confounders.
Baseline TAS andGSH levelswere signiﬁcantly lower in patients than healthy controls. In patients, baseline TASwas
positively associatedwith the global cognition score at baseline (p= 0.048) and two years later (p= 0.005), while
TAS was not associated with cognitive functioning in healthy controls. Further, baseline TAS in patients was
speciﬁcally associated with the memory domain at baseline and with the memory and attention domains two
years later. Stratifying by affective and non-affective psychoses, signiﬁcant associations were only found between
TAS and cognition in the non-affective psychosis group. Baseline GSH levels were not associated with cognitive
functioning at either time point in either group.
The antioxidant defence capacity in early onset ﬁrst-episode psychotic patients is directly correlated with global
cognition at baseline and at 2 years of follow-up, especially in non-affective psychosis.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
An imbalance between pro-oxidant and antioxidant mechanisms in
cells is thought to play a role in the pathophysiology ofmany diseases of
the central nervous system, such as schizophrenia (Fendri et al., 2006;
Bitanihirwe and Woo, 2011). As this imbalance is a potential cause ofrch Unit, University Hospital of Alav
kidetza.net (M. Martínez-Cengotitab
. This is an open access article underoxidative stress and damage to key brain circuits (van Os et al., 2010;
Andreazza, 2012; Anderson et al., 2013) the accumulation of pro-
oxidant molecules (i.e., reactive oxygen species) and/or impaired anti-
oxidant defence mechanisms (both enzymatic and non-enzymatic)
have become targets for study in psychotic disorders. The interest in
and the evidence to justify these studies come from previous researcha, Calle Olaguibel 29, 01004 Vitoria, Spain. Tel./fax: +34 945 007764.
engoa).
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Neuropsychological tests and variables grouped by cognitive domain.
Cognitive domain Neuropsychological variable
Attention WAIS-IIIa Digits Forward
Time to complete TMT-Ab
Number of correct items, Stroop 1 words
Number of correct items, Stroop 2 colours
Number of correct responses, CPTc
Average reaction time, CPT
Working memory WAIS-III Digits Backward
WAIS-III Number–Letter Sequencing
Learning and memory TAVECd Total Learning
TAVEC Short Term Free Recall
TAVEC Long Term Free Recall
TAVEC Discrimination
Executive functions Time to complete TMTBe
Number of words, FASf
Number of words, COWATg
Stroop Interference score
WCSTh number of perseverative errors
WCST number of errors
WCST conceptual level responses
a WAIS-III: Wechsler Adult Intelligence Scale, 3rd edition (Wechsler, 1997).
b TMT-A: Trail Making Test, part A (Spreen and Strauss, 1998).
c CPT: Conners' Continuous Performance Test (Conners, 2000).
d TAVEC: Spanish version (Benedet et al., 2001) of the California Verbal Learning Test
(Delis et al., 1994).
e TMTB: Trail Making Test, part B = (time to complete TMT-B − time to complete
TMT-A) ∕ time to complete TMT-A (Spreen and Strauss, 1998).
f FAS: Verbal ﬂuency test (Spreen and Strauss, 1998).
g COWAT: Control Oral Word Association Test. Semantic category “animals” (Benton,
1994).
h WCST: Wisconsin Card Sorting Test (Heaton, 1981; Spreen and Strauss, 1998).
24 M. Martínez-Cengotitabengoa et al. / Schizophrenia Research 156 (2014) 23–29in both adults (Anderson et al., 2013), children (Micó et al., 2011), and
their siblings (Ben Othmen et al., 2008).
In the search for biomarkers of functional or structural damage in psy-
chiatric disorders, early studies have suggested that total antioxidant sta-
tus (TAS) should be systematically measured given its association with
the pathophysiology of schizophrenia spectrum disorders (Ustundag
et al., 2006). TAS reﬂects the cumulative effects of all antioxidants present
in the plasma and other body ﬂuids. Studies measuring TAS have found
lower levels of antioxidants in patients with neuropsychiatric diseases
(such as schizophrenia and bipolar disorder) than in healthy controls
(Micó et al., 2011), as well as a dysfunctional balance of oxidative
and pro/anti-inﬂammatory pathways in ﬁrst-episode psychosis (FEP)
(García-Bueno et al., 2013). It is especially important to study the disease
at its outset as it is possible to ﬁnd pathophysiological clues uncontami-
nated by chronicity or drug effect (Bernardo et al., 2013).
It is also of relevance to psychosis that oxidative stress can promote
macro and microglial damage, including axonal demyelination (Qin
et al., 2008; rev. in Adibhatla and Hatcher, 2010). Indeed, it has recently
been shown that lower baseline plasma levels of the main cellular
antioxidant, glutathione (GSH) at the time of a ﬁrst psychotic episode
are associated with greater decreases in cortical grey matter two years
later in patients with early onset psychosis (Fraguas et al., 2012),
suggesting a role for oxidative damage in the pathophysiology of this
disease.
The relationship between oxidative stress and cognition has been
explored in some studies. In a previous study of adults with FEP, we
found that plasma GSH levels were positively associatedwith executive
functioning (Martinez-Cengotitabengoa et al., 2012). A recent study
found that higher activity of plasma manganese superoxide dismutase
(a mitochondrial enzyme that detoxiﬁes superoxide radicals to hydro-
gen peroxide) was signiﬁcantly correlated with the degree of cognitive
impairments in patients with schizophrenia (Zhang et al., 2013).
Although these ﬁndings support an association between oxidative
stress and cognitive deﬁcits, both studies were cross-sectional in design
and, to our knowledge, there have been no longitudinal studies.The objective of this study was to explore the long-term effects of
low baseline TAS andGSH levels on the cognitive functioning of patients
with early onset psychosis.We hypothesized that the antioxidant status
of patients during an early ﬁrst psychotic episode would be inversely
associated with their cognitive performance at baseline and two years
after the acute episode. Further, for this analysis, we stratiﬁed patients
into those with affective and non-affective psychoses.
2. Methods
2.1. Subjects
The original Child and Adolescent First-Episode Psychosis Study
(CAFEPS) was a case–control study that included 110 FEP patients
aged 9–17 years at the time of ﬁrst evaluation. Aﬁrst episode of psycho-
sis was deﬁned as the presence of positive psychotic symptoms of
delusions or hallucinations for a period of less than 6 months. This
short duration of symptomatology was used to obtain a more homoge-
nous patient sample. Patients were recruited fromChild and Adolescent
Psychiatry Units at six university hospitals in Spain. Sample recruitment
and patient characteristics have been described elsewhere (Castro-
Fornieles et al., 2007). Exclusion criteria were: the presence of any
other Axis I disorder that might account for the psychotic symptoms
(such as substance abuse, autistic spectrum disorders, post-traumatic
stress disorder, and acute stress disorder);mental retardation according
to DSM-IV criteria, including not only an intelligence quotient of less
than 70, but also impaired functioning; pervasive developmental
disorder; neurological disorders; a history of head trauma with loss of
consciousness; and pregnancy. Patientswere not excluded for occasion-
al substance use if positive symptoms persisted for more than two
weeks after a negative urine drug test.
The study also included 98 healthy control subjectswhowere select-
ed from the same catchment area and matched to the patients by age
and gender. They were selected from publicly-funded schools with
similar characteristics to those attended by patients through advertise-
ments and from children who were seen for routine paediatric visits at
our hospitals. The control subjects had no history of Axis I psychiatric
disorders, neurological disorders, mental retardation, or head trauma,
and were not pregnant, and there was no history of psychiatric disor-
ders in their ﬁrst-degree relatives.
Baseline blood samples for measuring oxidative stress were avail-
able for 105 patients and 97 controls of the original sample and these
individuals were included in the present analysis. The study was
approved by the Ethics and Clinical Research Boards of all the hospitals
involved in the study. Parents or legal guardians gave written informed
consent and patients assented to participate in the study.
2.2. Design and clinical assessment
In this prospective study, we assessed the antioxidant status of FEP
patients at baseline and evaluated their cognitive functioning at base-
line and two years later.
All patients met the DSM-IV criteria for a FEP (American Psychiatric
Association, 1994), assessed using the Kiddie Schedule for Affective Dis-
orders and Schizophrenia, Present and Lifetime Version (K-SADS-PL)
(Kaufman et al., 1997). Clinical assessments on admission and two
years later were performed by an experienced child psychiatrist with
speciﬁc training in the K-SADS-PL semi-structured interview. Socioeco-
nomic status was estimated using the Hollingshead and Redlich scale
(Hollingshead and Redlich, 1958), administered to the parents by the
same clinician.
2.3. Oxidative stress evaluation
Based on preliminary data (Micó et al., 2011), we focused the present
analyses on the following oxidative variables: TAS as a global measure of
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25M. Martínez-Cengotitabengoa et al. / Schizophrenia Research 156 (2014) 23–29antioxidant capacity, and the level of glutathione (GSH) as the main cel-
lular antioxidant. These variableswere determined as follows. Blood sam-
ples were taken from each patient at the time of admission and from the
healthy controls. Following centrifugation, the erythrocytes and plasma
were separated and stored frozen at−80 °C until analysis. All samples
were analysed at the same time. TAS was determined by standardised
spectrophotometric assays (Bioxytech, Beverly Hills, USA) in plasma.
Brieﬂy, the TAS assay relies on the ability of antioxidants present in plas-
ma to inhibit the oxidation of 2,2′-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid), monitored by measuring the absorbance at 600 nm.
Total GSH levels were determined by standardised spectrophotometric
assays (Bioxytech) of erythrocyte haemolysates. The assay is based on
the formation of a chromophoric thione, with the absorbance measured
at 420 nm being directly proportional to the GSH concentration.
2.4. Neurocognitive assessment
Cognitive assessments were carried out four to eight weeks after ad-
mission to allow time for acute symptoms to stabilize, and at two years
after illness onset. The battery of neurocognitive tests was designed to
assess four cognitive domains (attention, working memory, learning
and memory, and executive functioning) by combining selected individ-
ual measures from different tests (Table 1). The selection of measures for
each domain was based on the MATRICS battery (Green et al., 2004), as
well as on the psychometric characteristics of the tests (Lezak, 1995;
Strauss et al., 2006) and on previous studies using similar procedures
(Heinrichs and Zakzanis, 1998; Addington et al., 2003; de Mello Ayres
et al., 2010; Zabala et al., 2010). All testswere administered and scored ac-
cording to standardised instructions by psychologists trained in the use of
the instruments. The intra-class correlation coefﬁcient (ICC), calculated as
a measure of the inter-rater reliability, was between 0.95 and 0.99.
Raw test scoreswere converted to z-scores (mean=0; SD=1)based
on the performance of the healthy control group, to obtain an overall
score for each cognitive domain. For these, a higher score indicates a bet-
ter performance. z-Scores were truncated at−4.0 to exclude extremely
deviant scores. Mean summary scores were then calculated as the arith-
metic means of the individual scores obtained for each cognitive domain
(i.e., means of the aforementioned z-scores). The global cognitive score
was calculated as the arithmetic mean of the scores for the four cognitive
domains.
2.5. Data analyses
All statistical analyses were performed using PASW Statistics version
18 and differences were considered signiﬁcant when p b 0.05. The base-
line characteristics of patients and healthy controls were summarised
using descriptive statistics: means and standard deviations (SD) for con-
tinuous variables and frequencies for categorical variables. Comparisons
were made between the patient and control groups using the chi-
square test (categorical variables) or Mann–Whitney U test (continuous
variables). Multiple linear regression models were used to assess the
inﬂuence of oxidative stress on cognitive functioning and the results are
presented as Beta coefﬁcients with p-values after establishing the lack
of multicollinearity and independence of errors. As oxidative stress has
also been associated with tobacco consumption (Zhang et al., 2006,
2007) and antipsychotic treatment (Lepping et al., 2011), we controlled
for these variables in the model, using the number of chlorpromazine
equivalent doses in the case of antipsychotic treatment. We also
controlled for baseline differences in socioeconomic status.
3. Results
3.1. Sample characteristics
Table 2 summarises the characteristics of the patients and healthy
controls at baseline. Group comparisons identiﬁed signiﬁcant differences
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26 M. Martínez-Cengotitabengoa et al. / Schizophrenia Research 156 (2014) 23–29between the patient and control groups for tobacco abuse or dependence
(p b 0.001) and socioeconomic status (p= 0.014). The baseline antioxi-
dant status also differed between these groups, with the patients
having signiﬁcantly lower levels of antioxidants (p b 0.001) and
GSH (p = 0.007). Table 2 also presents the baseline characteristics of
the patients by their diagnostic category at the two-year follow-up
assessment (using DSM-IV criteria). Of the 80 patients who completed
the assessment both at baseline and two years later, 50 had non-
affective psychosis and 30 had affective psychosis at the two-year
follow-up. The non-affective psychosis group comprised patients with
schizophrenia (38) and psychotic disorder not otherwise speciﬁed (12),
while the affective psychosis group consisted of patients with a diagnosis
of bipolar disorder (19), psychotic depression (4) or schizoaffective disor-
der (7). Among these different diagnostic groups of patients, there were
no signiﬁcant differences in tobacco use, socioeconomic status or baseline
antioxidant status (Table 2).
3.2. Relationship between oxidative stress and cognition
Baseline TAS differed between tobacco abusers or dependants and
others (patients + controls) (U = 2247.0; p = 0.029), being higher
in the non-smoker group, while baseline GSH levels in these groups
were not signiﬁcantly different (U = 1897.5; p = 0.236). Within the
patient group, no signiﬁcant differences were found in the levels of
TAS and GSH between smokers and non-smokers (U = 980.0, p =
0.439; U = 625.0, p = 0.245).
Table 3 presents the mean z-scores for each of the four cognitive
domains and the global cognition scores in the patient and control
groups. Compared with the healthy control group, the FEP patients
had a poorer cognitive performance both at baseline and two years of
follow-up (p b 0.001 for all four domains). However, there was no dif-
ference in cognitive functioning between the affective psychosis group
and the non-affective psychosis group at either time point (Table 3).
Fig. 1 shows that in FEP patients baseline TAS levelswere signiﬁcant-
ly positively associated with the global cognition score at baseline (B=
0.405; p = 0.048) and two years later (B = 0.708; p = 0.005), after
controlling for confounding variables, while in the control group there
was no signiﬁcant association between baseline TAS and cognition at
either time point. In contrast, there were no signiﬁcant associations
between baseline GSH levels and global cognitive functioning at either
time point in either group (data not shown).
Table 4 summarises the associations between baseline TAS and
cognitive functioning at baseline and at two years of follow-up in the
patient and control groups, after controlling for confounding variables.
In the patient group, there was a signiﬁcant positive association
between baseline TAS and memory both at baseline and two years
later. In addition, in this group a higher TAS level at baselinewas associ-
ated with better attention at two-years of follow-up (Table 4).
Among the diagnostic subgroups of patients, in those with non-
affective psychosis at two years there was a direct relationship between
baseline TAS and attention, working memory and global cognition at
baseline, as well as a positive association between baseline TAS and
attention, memory, executive function and global cognition at two
years of follow-up (Table 4). In the groupwith affective psychosis, how-
ever, we found no signiﬁcant associations between baseline TAS and
cognitive functioning.
4. Discussion
In our sample of early onset psychotic patients, plasma total antioxi-
dant status at the onset of the illnesswas positively associatedwith global
cognitive performance both at baseline and at two years of follow-up,
after controlling for tobacco use, antipsychotic exposure at baseline and
socioeconomic status.
These ﬁndings are in line with studies, in vitro and in vivo, demon-
strating that the accumulation of oxidative and nitrosative mediators
Fig. 1. Association between baseline total antioxidant status (TAS) and global cognition score at (a) baseline and (b) after 2 years of follow-up.
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these harmful compounds in the central nervous system (Aksenova et al.,
2005; Fernández-Checa et al., 2010). Data from animal models suggest
that antioxidant depletion in the brain can cause cognitive impairment
(Dean et al., 2009) due to cellular lack of resilience and damage that, if
not repaired, can lead to altered physiology and cognitive dysfunction
(Pedrini et al., 2012). These ﬁndings reinforce the need to evaluate pa-
tients at the prodromal phase and all those in ultra-high risk groups, in
order to avoid the deleterious consequences of the oxidative stress of
the ﬁrst psychotic episode.
Our results support the view that oxidative stress, in patients with
early psychosis, but not in healthy controls, may alter some neuropro-
tective factors that are essential for cognitive tasks (Cabungcal et al.,
2013; Dodd et al., 2013). The reduced capacity to protect against free
radicals found in our sample of early onset patients (Mico et al., 2011)
could lead to membrane dysfunction and DNA damage contributing to
and explaining the speciﬁc symptoms of these patients, such as cogni-
tive dysfunction (Martinez-Cengotitabengoa et al., 2012). On the other
hand, previous studies have highlighted the role of NMDA-receptors
in memory functioning (Morris et al., 2013). It seems as if a lower
level of antioxidant protection could inﬂuence the normal functioning
of NMDA receptors, causing abnormal functioning of memory processes
(Kantrowitz and Javitt, 2010; Javitt et al., 2012).
The analysis of diagnostic subgroups yielded an interesting ﬁnding.
Namely, the insult of oxidative stress at baseline affects affective andTable 4
Association between baseline total antioxidant status (TAS) and cognitive functioning at baseli
tipsychotic treatment and socioeconomic status.
Cognitive domain
Attention Working memory
B p-Value B p-Value
At baseline
Healthy controls (N = 97) −0.016 0.915 −0.236 0.199
Patients (N = 105) 0.381 0.088 0.462 0.109
Non-affective psychosis (n = 50) 0.516 0.042 0.653 0.037
Affective psychosis (n = 30) 0.084 0.913 0.641 0.544
Data missing (n = 25) −0.169 0.775 −0.069 0.919
At 2 years of follow-up
Healthy controls (N = 97) −0.155 0.322 −0.105 0.601
Patients (N = 105) 0.705 0.015 0.517 0.079
Non-affective psychosis (n = 50) 0.704 0.032 0.393 0.189
Affective psychosis (n = 30) 0.651 0.387 0.772 0.337
Data missing (n = 25) NA NA
Items in bold indicate statistical signiﬁcance.
B = Beta coefﬁcient.
NA = No data available at 2 year assessment.non-affective psychotic patients in a different manner both at baseline
and follow-up. Speciﬁcally, baseline TAS is related to cognition in non-
affective psychosis, but not in affective psychosis. The different relation-
ship between TAS and cognition at baseline and two years after onset in
the two types of psychosis could be related not only to a different
aetiology for the cognitive deﬁcit, but also to a different capacity of
modulating damage in affective disorders, at least in the earlier stages
of the illness. We cannot exclude the impact of some factors that were
not measured, such as antioxidant status during follow-up. In addition,
we cannot conclude that there is no type II error in the subsample of
patients with affective disorder.
To date, it has been shown that there is a relationship between
oxidative stress and clinical severity both in bipolar disorder during a
depressive or a manic episode (Raffa et al., 2012; Kulak et al., 2013),
and inmajor depression (Tobe, 2013). A relationship between cognition
and oxidative stress has also been observed in chronic bipolar patients
(Vieta et al., 2013) but there are no previous studies analysing the rela-
tionships between TAS and cognition in the medium term. Although
these results need conﬁrmation by new research, they suggest that
the inability of the systemic antioxidant defences to control activated
pro-oxidant pathways, that may underlie the insult produced by an
early psychotic episode, persists and may contribute to cognitive
outcome two years after the initial episode. Our work also indicates
the potential predictive value of TAS as a peripheral biomarker of cogni-
tive impairments, as it reﬂects overall antioxidant capacity including thene and at 2 years of follow-up: results of regression models controlled for tobacco use, an-
Global cognition
Memory Executive function
B p-Value B p-Value B p-Value
0.019 0.919 0.007 0.958 −0.059 0.601
0.905 0.019 0.148 0.502 0.405 0.048
0.760 0.097 0.450 0.089 0.514 0.028
0.904 0.431 −0.790 0.320 0.170 0.814
0.653 0.484 −0.378 0.349 0.019 0.971
0.139 0.432 −0.031 0.795 −0.057 0.584
1.241 0.012 0.419 0.090 0.708 0.005
1.124 0.040 0.504 0.043 0.663 0.013
0.972 0.449 −0.529 0.452 0.352 0.606
NA NA
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associated with cognition in this research, although it has previously
been associated with psychosis (Mico et al., 2011).
Our results also support the suggestion made by other authors of
prescribing antioxidants to treat schizophrenia (Mahadik et al., 2006;
Deanet al., 2011; Reddy et al., 2011) due to the involvement of oxidative
stress in several processes occurring over the course of the illness
including cognitive impairment. We underline that these antioxidants
could be used in the very early stages, as a more benign form of treat-
ment, attempting to delay the introduction of antipsychotic medication
in early onset patients and, thereby, avoid the adverse events of such
medications for as long as possible as suggested by some other authors
(Francey et al., 2010), and also combining their effects with those of
antipsychotic medication, ideally enabling lower doses to be used in
children and adolescents. However, for this approach to be adopted in
routine practice, further research is needed to demonstrate the useful-
ness of antioxidants in schizophrenia.
Lastly, our ﬁndings point to the possibility of using peripheral
markers of oxidative and antioxidative balance in patients with ﬁrst-
episode psychosis, for prognostic and preventive purposes, taking into
account the high sensitivity of the brain to oxidative damage (Ng
et al., 2008) that is reﬂected in multiple stress-mediated responses
such as cognitive dysfunction in individuals with impaired antioxidant
defence.
This study has various limitations and strengths. It is a prospective
naturalistic study but biochemical parameters (TAS and GSH levels)
were only measured at baseline. A second limitation is that, though
this is a multicentre study, the majority of participating centres were
hospital units that had an inpatient facility and this may represent a
bias towards the inclusion of more severe cases, making it difﬁcult to
generalize the results to less severe ones. On the other hand, nearly
70% of patients with early psychosis are hospitalized (Murphy et al.,
2009). A third limitation is that we assume that changes in peripheral
blood levels adequately reﬂect changes in the mental state of the
brain. The last limitation to mention is that we cannot exclude
completely that nutritional status or lifestyle could have had an effect
on the results, although most of the patients had similar nutritional
and lifestyle at the time of TAS assessment due to their inpatient status.
One of the study strengths is the homogeneity of the sample and the ex-
istence of a control group. Further, a relevant strength is that compared
with studies with similar design characteristics, our patient sample is
the largest reported to date to detect predictive variables for a cohort
in early psychosis.
In conclusion, our study shows that the antioxidant defence sys-
tem in patients with early onset ﬁrst-episode psychosis has an in-
verse correlation with global cognition at baseline and at two years
of follow-up. Oxidative damage may contribute to the pathophysiol-
ogy and account for a poor cognitive function in this early onset
group. Future research should consider chronic stages stratifying
by diagnostic subgroups to clarify the possible utility of TAS as a pe-
ripheral marker of oxidative stress and as a prognostic factor for each
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